Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 09 October 2017 | By Michael Mezher
The European Medicines Agency (EMA) on Monday updated its annex to the European Commission's guideline on excipient labeling, adding five new excipients and expanding the safety warnings required for 10 others.
Excipients are defined as any part of a drug other than the active pharmaceutical ingredient. Most excipients are thought to be inactive, though some can cause reactions in certain circumstances. For instance, lactose is commonly used as a filler in drug tablets, but can cause reactions in patients who are lactose intolerant.
The document, which lists the excipients that are "known to have a recognized action or effect" that must be declared in a medicine's label and package leaflet, is being updated for the first time since its publication in 2003.
The update also comes as the European Commission considers revisions to its excipient labeling guideline following a public consultation that closed in May.
The five newly listed excipients include boric acid, cyclodextrins, phosphate buffers, sodium laurilsulfate and fragrances containing allergens. The annex includes an appendix listing 26 specific fragrance allergens such as cinnamal and oak moss that are required to be included in labeling.
As for the new safety information, EMA says the revised annex "pays specific attention to…the safety of these excipients when used in children or pregnant women." For example, the annex includes new safety information that must be listed in the package leaflet for drugs containing benzyl alcohol advising women who are pregnant or breast feeding to consult with their doctor or pharmacist before taking the drug.
EMA says the revised annex goes into effect immediately for all centrally and nationally authorized medicines, and current marketing authorization holders are instructed to update their product labeling at the first opportunity. For products with no upcoming regulatory submissions, EMA says sponsors should submit a type IB variation detailing any labeling changes within the next three years.
EMA
Tags: Excipients, Labeling, Package Leaflet
Regulatory Focus newsletters
All the biggest regulatory news and happenings.